BriaCell Therapeutics Corp. (TSE:BCT – Get Free Report) traded down 0.8% during trading on Wednesday . The company traded as low as C$4.74 and last traded at C$4.74. 131 shares changed hands during trading, a decline of 99% from the average daily volume of 17,928 shares. The stock had previously closed at C$4.78.
BriaCell Therapeutics Trading Down 1.5%
The firm’s fifty day moving average price is C$4.70 and its two-hundred day moving average price is C$5.24. The stock has a market capitalization of C$41.15 million, a PE ratio of -5.63 and a beta of 1.96.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to developing novel immunotherapies to fight cancer and improve patients’ lives. Immunotherapies have become the forefront of the fight against cancer because they use the body’s immune system to destroy cancer cells, offer the potential for higher levels of safety and efficacy than chemotherapy, and may also prevent cancer recurrence.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
